TRVN - Trevena, Inc.
1.48 +0.01 (0.68%)
After hours: 7:57PM EST
| Previous Close | 1.3900 |
| Open | 1.3900 |
| Bid | 1.40 x 1400 |
| Ask | 1.48 x 1800 |
| Day's Range | 1.3500 - 1.4700 |
| 52 Week Range | 0.3820 - 3.5780 |
| Volume | 2,582,713 |
| Avg. Volume | 3,425,257 |
| Market Cap | 135.715M |
| Beta (3Y Monthly) | 5.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings Date | Mar 5, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
- Simply Wall St.•15 days ago
How Much Of Trevena, Inc. (NASDAQ:TRVN) Do Institutions Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
- Zacks•15 days ago
Will Trevena Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Trevena.
- ACCESSWIRE•16 days ago
Biotech Stocks Set to Pop
HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...
- ACCESSWIRE•16 days ago
Top Cannabis and Biotech Stocks To Watch
HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...
- GlobeNewswire•17 days ago
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
- GlobeNewswire•22 days ago
Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- American City Business Journals•23 days ago
Trevena to sell stock, makes progress on resubmitting new drug application
The Chester County biopharmaceutical expects to initiate a new study for its experimental pain medicine, requested by the FDA, during the first half of this year.
- ACCESSWIRE•24 days ago
Opioid Abuse and Dependent Therapies, Here is What Travena is Doing to Tackle this Problem
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Trevena, Inc. (TRVN), a biopharmaceutical company that has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. The management strongly believes in the utility of oliceridine as a new analgesic option for the management of moderate to severe acute pain for patients in hospitals or other controlled clinical settings and has laid out a detailed plan to capitalize this opportunity and gain approval for Oliceridine. Trevena was founded to translate Nobel Prize-winning research into a new generation of ground-breaking medicines.
- GlobeNewswire•24 days ago
Trevena Announces $10 Million Registered Direct Offering of Common Stock
Trevena, Inc. (TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of 10,000,000 shares of its common stock at an offering price of $1.00 per share, in a registered direct offering, for gross proceeds of $10.0 million, before deducting placement agent fees and offering expenses payable by Trevena. The offering is expected to close on or about February 1, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
- Market Realist•25 days ago
Trevena Jumped by 119.96% Yesterday
Trevena Stock Soars on Positive Response from FDAStock price jumpOn January 28, Trevena (TRVN) closed at $1.19, which is 119.96% higher than its previous closing price. This spike was in response to the company’s press release that announced the
- ACCESSWIRE•26 days ago
4 Healthcare Stocks Looking For A Healthy Start On Monday (1/28/19)
With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
- GlobeNewswire•26 days ago
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) today announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA).
- GlobeNewswire•2 months ago
National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology as part of Trevena’s ongoing collaboration with the National Institute on Drug Abuse (NIDA). The presentation, entitled “Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience Research Branch, Intramural Research Program at NIDA.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena — Future Expectations, Projections Moving into 2018
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: TRVN GOOG GOOGL CWH HON FIT SYF RYAAY TSRO MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Dec. 10, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•2 months ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline - December 10, 2018
Attorney Advertising--(PR Newswire)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (TRVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Trevena securities between May 2, 2016 and October 8, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/trvn. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants misled shareholders to believe that the April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration (“FDA”) was more successful than it really was.
- GlobeNewswire•2 months ago
Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced the promotion of Robert T. Yoder from Vice President Commercial Operations and Sales to the newly created position of Senior Vice President and Chief Business Officer, effective immediately. Mr. Yoder brings to this position over 30 years of industry experience across a wide range of functions and therapeutic areas, including acute care. “Since joining Trevena in June, Bob has taken on increasing leadership within the Company and has played a large role in our efforts towards the ultimate approval of oliceridine,” said Carrie L. Bourdow, President and Chief Executive Officer.
- ACCESSWIRE•3 months ago
FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Reminds Investors with Losses in Excess of $200,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (''Trevena'' or ''the Company'') (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 2, 2016 and October 8, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before December 10, 2018.
- Business Wire•3 months ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Trevena, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Trevena, Inc. (“Trevena” or the “Company”) (TRVN) of the December 10, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Trevena stock or options between May 2, 2016 and October 8, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/TRVN.
- GlobeNewswire•3 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY
NEW YORK, Dec. 07, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- Business Wire•3 months ago
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire•3 months ago
SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Dec. 06, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- Business Wire•3 months ago
MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- ACCESSWIRE•3 months ago
MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Reminds Investors with Losses in Excess of $200,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 6, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (''Trevena'' or ''the Company'') (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 2, 2016 and October 8, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before December 10, 2018.
